Asked by: Liam Byrne (Labour - Birmingham, Hodge Hill)
Question to the Foreign, Commonwealth & Development Office:
To ask the Minister of State, Foreign, Commonwealth and Development Office, what recent assessment he has made of the effectiveness of the Wassenaar Arrangement in controlling the dual-use export of (a) artificial intelligence, (b) quantum computing, (c) biometric tools and data and (d) intangible technology transfers.
Answered by Anne-Marie Trevelyan - Minister of State (Foreign, Commonwealth and Development Office)
The Wassenaar Arrangement is a long-established multilateral export control regime which operates by consensus. It includes the majority of states producing these advanced technologies and draws on expertise from all members to develop control lists, which are updated annually. These lists are used by participating states to implement their export controls and, as the Wassenaar Arrangement sets the global standard for good practice, non-member states also incorporate the control lists into their domestic legislation.
The UK is an active member of the Wassenaar Arrangement and other multilateral export control regimes. We submit and review proposals related to these advanced technologies, share best practice, and participate in outreach to non-member states. We are co-ordinating with G7 and other partners to strengthen export controls, including to update multilateral export control regime lists to keep pace with rapid technological developments.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, what plans they have to use artificial intelligence systems to support the diagnosis of prostate cancer, as recommended by the Lancet Commission in research published on 4 April.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the Lancet Commission on prostate cancer, published 4 April 2024.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to expand public awareness campaigns for prostate cancer, following the prediction by the Lancet Commission of a surge in cases.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Lord Bishop of St Albans (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to recent research conducted by the Lancet Commission, what steps they plan to take to address the projected surge in prostate cancer cases.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
Prostate cancer is the most common cancer in men in the United Kingdom, and currently has no screening programme. The recently announced TRANSFORM trial aims to find the best way to screen for prostate cancer. This study is led by Prostate Cancer UK and supported by £42 million of Government funding.
In March 2024, NHS England implemented the Faster Diagnosis Standard (FDS), setting a target of a maximum 28 day wait from urgent suspected general practice or screening referral to patients being told they have cancer, or that cancer is ruled out. To achieve this target, NHS England is streamlining cancer pathways by introducing best-practice timed pathways for prostate cancer, so that those suspected of having prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures only those men most at risk of having cancer undergo an invasive biopsy. As well as diagnosing patients faster, NHS England is working to diagnose patients at an earlier stage, through the ambitions set out in the NHS Long-Term Plan, to diagnose 75% of cancers at stages one and two by 2028.
NHS England takes steps to raise awareness of prostate cancer, where there are opportunities to do so. For example, NHS England partners with Cancer Alliances, charities, and local representatives to reach people through projects in the heart of their communities. Cancer Alliances have also been undertaking action to alert at-risk groups about prostate cancer. This is determined at a local level, and so will vary depending on local needs and priorities.
The Government has made significant strides in enabling the use of artificial intelligence (AI) systems to support the diagnosis of many types of cancer, including prostate. The AI in Health and Care Award was established, aiming to accelerate the testing and development of AI technologies that align with the NHS Long Term Plan. The award represents a substantial investment in the future of healthcare technology, with £113 million already allocated to support 86 AI technologies. Three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford. This AI-based diagnostic software aids in the interpretation of pathology sample images, facilitating more efficient detection, grading, and quantification of cancer in prostate biopsies. The Chancellor’s recent budget announcement on 6 March 2024 includes a £3.4 billion investment to reform how the National Health Service works, including on the use of technologies such as AI.
Finally, although no specific assessment of the Lancet Commission published 4 April 2024 has been made, the Department will work with NHS England to review the details.
Asked by: Liam Byrne (Labour - Birmingham, Hodge Hill)
Question to the Department for Business and Trade:
To ask the Secretary of State for Business and Trade, what assessment she has made of the effectiveness of UK export controls in controlling the proliferation of sensitive technology in the areas of (a) artificial intelligence, (b) quantum, (c) biometric tools and (d) intangible technology transfers.
Answered by Alan Mak - Minister of State (Department for Business and Trade) (jointly with the Cabinet Office)
The Government has been reviewing export controls and their application to sensitive emerging technologies across a range of sectors.
We are looking shortly to publish the results of that review and launch a public consultation on the process for ensuring the controls evolve to meet the challenge of new and emerging technologies.
Asked by: Emma Lewell-Buck (Labour - South Shields)
Question to the Ministry of Defence:
To ask the Secretary of State for Defence, when he plans to publish the Defence AI Skills Framework.
Answered by James Cartlidge - Minister of State (Ministry of Defence)
The development of a Defence AI Skills Framework is underway, and we expect work to accelerate following the recruitment of our Capability Lead for AI Talent and Skills. We are working closely with Digital Skills for Defence (DS4D) and other key stakeholders to ensure coherence with other complimentary skills frameworks within the department, but also across government and with allies.
Asked by: Liam Byrne (Labour - Birmingham, Hodge Hill)
Question to the Department for Business and Trade:
To ask the Secretary of State for Business and Trade, what role the National Cyber Security Centre plays in facilitating export controls to prevent the proliferation of sensitive technology in the areas of (a) artificial intelligence, (b) quantum computing, (c) biometric tools and data and (d) intangible technology transfers.
Answered by Alan Mak - Minister of State (Department for Business and Trade) (jointly with the Cabinet Office)
The National Cyber Security Centre is HM Government’s national technical authority for information security and advises the Export Control Joint Unit, in the Department for Business and Trade, on export licence applications for goods involving sensitive communications or computer technology.
Asked by: Emma Lewell-Buck (Labour - South Shields)
Question to the Ministry of Defence:
To ask the Secretary of State for Defence, with reference to the Defence Artificial Intelligence Strategy, published on 15 June 2022, whether his Department has appointed a Head of AI Profession.
Answered by James Cartlidge - Minister of State (Ministry of Defence)
The Defence AI Centre (DAIC) is currently onboarding a Capability Lead, AI Talent and Skills. They are expected to be in post in quarter 2 of this financial year.
This individual will work with colleagues across Government to advance the AI skills agenda while also exploring novel ways to attract talent into the department.
Asked by: Debbie Abrahams (Labour - Oldham East and Saddleworth)
Question to the Department for Work and Pensions:
To ask the Secretary of State for Work and Pensions, whether the (a) Integrated Risk and Intelligence Service, (b) Enhanced Checking Service, (c) Risk Review Team, (d) Enhanced Review Teams, (e) Universal Credit advances claims decision risk model, (f) Common Risk Engine, (g) General Matching Service, (h) Fraud Referral and Intervention Management System, (i) Targeted Case Review and (j) any other systems rely on artificial intelligence, machine learning or algorithmic processes for fraud detection.
Answered by Paul Maynard - Parliamentary Under-Secretary (Department for Work and Pensions)
As set out in the Department’s 2022/23 Annual Report and Accounts (page 308 to 310), DWP uses advanced analytics to tackle fraud and error. These analytics include a variety of sophisticated techniques including the use of machine learning to identify patterns in claims that could suggest fraud or error, so that these claims can be reviewed by relevant DWP teams such as the Enhanced Review Team. The final decision on benefit entitlement is made by a human caseworker.
The National Audit Office confirm that DWP have governance and processes in place to monitor the bias of these models.